Open AccessTreatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
Author(s) -
Win Hninyee,
Gowin Krisstina
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3302
Subject(s) - lenalidomide , medicine , bortezomib , dexamethasone , refractory (planetary science) , dermatology , thalidomide , multiple myeloma , oncology , physics , astrobiology
Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.